Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.

Grönlund MM, Remes-Pakarinen T, Kröger L, Markula-Patjas K, Backström M, Putto-Laurila A, Aalto K, Vähäsalo P.

Rheumatology (Oxford). 2019 Jul 29. pii: kez291. doi: 10.1093/rheumatology/kez291. [Epub ahead of print]

PMID:
31359057
2.

Participation in school and physical education in juvenile idiopathic arthritis in a Nordic long-term cohort study.

Nordal E, Rypdal V, Arnstad ED, Aalto K, Berntson L, Ekelund M, Fasth A, Glerup M, Herlin T, Nielsen S, Peltoniemi S, Zak M, Songstad NT, Rygg M; Nordic Study Group of Pediatric Rheumatology (NoSPeR).

Pediatr Rheumatol Online J. 2019 Jul 15;17(1):44. doi: 10.1186/s12969-019-0341-6.

3.

Pain interference and associated factors in young adults with juvenile idiopathic arthritis.

Rebane K, Orenius T, Ristolainen L, Relas H, Kautiainen H, Luosujärvi R, Säilä H, Aalto K.

Scand J Rheumatol. 2019 Jun 7:1-7. doi: 10.1080/03009742.2019.1596308. [Epub ahead of print]

PMID:
31170850
4.

Validating 10-joint juvenile arthritis disease activity score cut-offs for disease activity levels in non-systemic juvenile idiopathic arthritis.

Backström M, Tynjälä P, Aalto K, Grönlund MM, Ylijoki H, Putto-Laurila A, Kärki J, Keskitalo P, Sard S, Pohjankoski H, Hietanen M, Witter S, Lehto H, Löyttyniemi E, Vähäsalo P.

RMD Open. 2019 Apr 24;5(1):e000888. doi: 10.1136/rmdopen-2018-000888. eCollection 2019.

5.

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort.

Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T; Nordic Study Group of Pediatric Rheumatology (NoSPeR).

Arthritis Care Res (Hoboken). 2019 Feb 14. doi: 10.1002/acr.23853. [Epub ahead of print]

PMID:
30762291
6.

Disability and health-related quality of life are associated with restricted social participation in young adults with juvenile idiopathic arthritis.

Rebane K, Ristolainen L, Relas H, Orenius T, Kautiainen H, Luosujärvi R, Aalto K, Säilä H.

Scand J Rheumatol. 2019 Mar;48(2):105-113. doi: 10.1080/03009742.2018.1493140. Epub 2018 Sep 30.

PMID:
30270708
7.

Early Self-Reported Pain in Juvenile Idiopathic Arthritis as Related to Long-Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study.

Arnstad ED, Rypdal V, Peltoniemi S, Herlin T, Berntson L, Fasth A, Nielsen S, Glerup M, Ekelund M, Zak M, Aalto K, Nordal E, Romundstad PR, Rygg M; Nordic Study Group of Pediatric Rheumatology.

Arthritis Care Res (Hoboken). 2019 Jul;71(7):961-969. doi: 10.1002/acr.23715. Epub 2019 Jun 12.

PMID:
30055093
8.

Predicting unfavorable long-term outcome in juvenile idiopathic arthritis: results from the Nordic cohort study.

Rypdal V, Arnstad ED, Aalto K, Berntson L, Ekelund M, Fasth A, Glerup M, Herlin T, Nielsen S, Peltoniemi S, Zak M, Rygg M, Rypdal M, Nordal E; Nordic Study Group of Pediatric Rheumatology (NoSPeR).

Arthritis Res Ther. 2018 May 3;20(1):91. doi: 10.1186/s13075-018-1571-6.

9.

The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).

Lahdenne P, Aalto K, Rebane K, Vahasalo P, Putto-Laurila AK, Malin M, Kroger L, Saila H, Consolaro A, Bovis F, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO).

Rheumatol Int. 2018 Apr;38(Suppl 1):179-186. doi: 10.1007/s00296-018-3950-3. Epub 2018 Apr 7.

10.

Cryopyrin-associated periodic syndrome in early childhood can be successfully treated with interleukin-1 blockades.

Eskola V, Pohjankoski H, Kröger L, Aalto K, Latva K, Korppi M.

Acta Paediatr. 2018 Apr;107(4):577-580. doi: 10.1111/apa.14217. Epub 2018 Feb 5.

PMID:
29331074
11.

Anti-adalimumab antibodies in juvenile idiopathic arthritis-related uveitis.

Leinonen ST, Aalto K, Kotaniemi KM, Kivelä TT.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):1043-1046. Epub 2017 Nov 14.

PMID:
29148422
12.

Incidence and predictors of Uveitis in juvenile idiopathic arthritis in a Nordic long-term cohort study.

Nordal E, Rypdal V, Christoffersen T, Aalto K, Berntson L, Fasth A, Herlin T, Nielsen S, Peltoniemi S, Straume B, Zak M, Rygg M; Nordic Study Group of Pediatric Rheumatology (NoSPeR).

Pediatr Rheumatol Online J. 2017 Aug 18;15(1):66. doi: 10.1186/s12969-017-0195-8.

13.

Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study.

Ekelund M, Aalto K, Fasth A, Herlin T, Nielsen S, Nordal E, Peltoniemi S, Rygg M, Zak M, Berntson L; Nordic Study Group of Pediatric Rheumatology (NoSPeR).

Pediatr Rheumatol Online J. 2017 Feb 22;15(1):13. doi: 10.1186/s12969-017-0145-5.

14.

Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use.

Aalto K, Lahdenne P, Kolho KL.

Pediatr Rheumatol Online J. 2017 Jan 31;15(1):9. doi: 10.1186/s12969-016-0132-2.

15.

Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors.

Ahola-Olli AV, Würtz P, Havulinna AS, Aalto K, Pitkänen N, Lehtimäki T, Kähönen M, Lyytikäinen LP, Raitoharju E, Seppälä I, Sarin AP, Ripatti S, Palotie A, Perola M, Viikari JS, Jalkanen S, Maksimow M, Salomaa V, Salmi M, Kettunen J, Raitakari OT.

Am J Hum Genet. 2017 Jan 5;100(1):40-50. doi: 10.1016/j.ajhg.2016.11.007. Epub 2016 Dec 15.

16.

Deregulation of ocular nucleotide homeostasis in patients with diabetic retinopathy.

Loukovaara S, Sandholm J, Aalto K, Liukkonen J, Jalkanen S, Yegutkin GG.

J Mol Med (Berl). 2017 Feb;95(2):193-204. doi: 10.1007/s00109-016-1472-6. Epub 2016 Sep 16.

PMID:
27638339
17.

Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence.

Wang Q, Würtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, Tiainen M, Tynkkynen T, Joensuu A, Havulinna AS, Aalto K, Salmi M, Blankenberg S, Zeller T, Viikari J, Kähönen M, Lehtimäki T, Salomaa V, Jalkanen S, Järvelin MR, Perola M, Raitakari OT, Lawlor DA, Kettunen J, Ala-Korpela M.

Int J Epidemiol. 2016 Oct;45(5):1445-1457. Epub 2016 Aug 18.

18.

The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection.

Ritchie SC, Würtz P, Nath AP, Abraham G, Havulinna AS, Fearnley LG, Sarin AP, Kangas AJ, Soininen P, Aalto K, Seppälä I, Raitoharju E, Salmi M, Maksimow M, Männistö S, Kähönen M, Juonala M, Ripatti S, Lehtimäki T, Jalkanen S, Perola M, Raitakari O, Salomaa V, Ala-Korpela M, Kettunen J, Inouye M.

Cell Syst. 2015 Oct 28;1(4):293-301. doi: 10.1016/j.cels.2015.09.007. Epub 2015 Oct 22.

19.

[Special features of biological drug therapy in children].

Aalto K, Leinonen S, Kolho KL, Lahdenne P.

Duodecim. 2016;132(4):377-82. Review. Finnish.

PMID:
27017790
20.

Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre study.

Backström M, Tynjälä P, Ylijoki H, Aalto K, Kärki J, Pohjankoski H, Keskitalo P, Sard S, Hietanen M, Lehto H, Kauko T, Vähäsalo P.

Rheumatology (Oxford). 2016 Apr;55(4):615-23. doi: 10.1093/rheumatology/kev353. Epub 2015 Oct 7. Review.

PMID:
26447164
21.

Body composition and adipokines in patients with juvenile idiopathic arthritis and systemic glucocorticoids.

Markula-Patjas K, Valta H, Pekkinen M, Andersson S, Aalto K, Lahdenne P, Viljakainen H, Mäkitie O.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6):924-30. Epub 2015 Aug 27.

PMID:
26315132
22.

Ankle arthritis predicts polyarticular disease course and unfavourable outcome in children with juvenile idiopathic arthritis.

Esbjörnsson AC, Aalto K, Broström EW, Fasth A, Herlin T, Nielsen S, Nordal E, Peltoniemi S, Rygg M, Zak M, Berntson L; Nordic Study Group of Paediatric Rheumatology (NoSPeR).

Clin Exp Rheumatol. 2015 Sep-Oct;33(5):751-7. Epub 2015 Jul 23.

PMID:
26213158
23.

Aberrant circulating levels of purinergic signaling markers are associated with several key aspects of peripheral atherosclerosis and thrombosis.

Jalkanen J, Yegutkin GG, Hollmén M, Aalto K, Kiviniemi T, Salomaa V, Jalkanen S, Hakovirta H.

Circ Res. 2015 Mar 27;116(7):1206-15. doi: 10.1161/CIRCRESAHA.116.305715. Epub 2015 Feb 2.

PMID:
25645301
24.

Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis.

Weston CJ, Shepherd EL, Claridge LC, Rantakari P, Curbishley SM, Tomlinson JW, Hubscher SG, Reynolds GM, Aalto K, Anstee QM, Jalkanen S, Salmi M, Smith DJ, Day CP, Adams DH.

J Clin Invest. 2015 Feb;125(2):501-20. doi: 10.1172/JCI73722. Epub 2014 Dec 22.

25.

[Still's disease--juvenile arthritis with systemic onset].

Kröger L, Putto-Laurila A, Vähäsalo P, Malin M, Aalto K.

Duodecim. 2014;130(16):1615-21. Review. Finnish.

PMID:
25269367
26.

Early prediction of persistent organ failure by soluble CD73 in patients with acute pancreatitis*.

Maksimow M, Kyhälä L, Nieminen A, Kylänpää L, Aalto K, Elima K, Mentula P, Lehti M, Puolakkainen P, Yegutkin GG, Jalkanen S, Repo H, Salmi M.

Crit Care Med. 2014 Dec;42(12):2556-64. doi: 10.1097/CCM.0000000000000550.

PMID:
25126879
27.

Distribution and medical impact of loss-of-function variants in the Finnish founder population.

Lim ET, Würtz P, Havulinna AS, Palta P, Tukiainen T, Rehnström K, Esko T, Mägi R, Inouye M, Lappalainen T, Chan Y, Salem RM, Lek M, Flannick J, Sim X, Manning A, Ladenvall C, Bumpstead S, Hämäläinen E, Aalto K, Maksimow M, Salmi M, Blankenberg S, Ardissino D, Shah S, Horne B, McPherson R, Hovingh GK, Reilly MP, Watkins H, Goel A, Farrall M, Girelli D, Reiner AP, Stitziel NO, Kathiresan S, Gabriel S, Barrett JC, Lehtimäki T, Laakso M, Groop L, Kaprio J, Perola M, McCarthy MI, Boehnke M, Altshuler DM, Lindgren CM, Hirschhorn JN, Metspalu A, Freimer NB, Zeller T, Jalkanen S, Koskinen S, Raitakari O, Durbin R, MacArthur DG, Salomaa V, Ripatti S, Daly MJ, Palotie A; Sequencing Initiative Suomi (SISu) Project.

PLoS Genet. 2014 Jul 31;10(7):e1004494. doi: 10.1371/journal.pgen.1004494. eCollection 2014 Jul.

28.

Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA).

Berntson L, Nordal E, Fasth A, Aalto K, Herlin T, Nielsen S, Rygg M, Zak M, Rönnelid J; Nordic Study Group of Pediatric Rheumatology (NoSPeR).

Pediatr Rheumatol Online J. 2014 Jun 11;12:22. doi: 10.1186/1546-0096-12-22. eCollection 2014.

29.

Soluble vascular adhesion protein-1 predicts incident major adverse cardiovascular events and improves reclassification in a finnish prospective cohort study.

Aalto K, Havulinna AS, Jalkanen S, Salomaa V, Salmi M.

Circ Cardiovasc Genet. 2014 Aug;7(4):529-35. doi: 10.1161/CIRCGENETICS.113.000543. Epub 2014 May 21.

PMID:
24850810
30.

Complementary and alternative medicine use in adolescents with inflammatory bowel disease and juvenile idiopathic arthritis.

Nousiainen P, Merras-Salmio L, Aalto K, Kolho KL.

BMC Complement Altern Med. 2014 Apr 4;14:124. doi: 10.1186/1472-6882-14-124.

31.

HLA-B27 predicts a more chronic disease course in an 8-year followup cohort of patients with juvenile idiopathic arthritis.

Berntson L, Nordal E, Aalto K, Peltoniemi S, Herlin T, Zak M, Nielsen S, Rygg M; Nordic Study Group of Paediatric Rheumatology.

J Rheumatol. 2013 May;40(5):725-31. doi: 10.3899/jrheum.121257. Epub 2013 Apr 1.

PMID:
23547219
32.

Prevention of infusion reactions to infliximab in paediatric patients with oral acetylsalicylic acid.

Hämäläinen A, Lahdenne P, Wikström A, Aalto K, Kolho KL.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4):590-1. Epub 2012 Aug 29. No abstract available.

PMID:
22766212
33.

[Medical treatment of juvenile idiopathic arthritis].

Kröger L, Vähäsalo P, Tynjälä P, Aalto K, Säilä H, Malin M, Putto-Laurila A, Lahdenne P.

Duodecim. 2012;128(5):477-86. Review. Finnish.

PMID:
22486063
34.

Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population-based setting.

Nordal EB, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Peltoniemi S, Straume B, Rygg M.

Ann Rheum Dis. 2012 Jul;71(7):1122-7. doi: 10.1136/annrheumdis-2011-200237. Epub 2012 Jan 17.

PMID:
22258487
35.

Soluble vascular adhesion protein-1 correlates with cardiovascular risk factors and early atherosclerotic manifestations.

Aalto K, Maksimow M, Juonala M, Viikari J, Jula A, Kähönen M, Jalkanen S, Raitakari OT, Salmi M.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):523-32. doi: 10.1161/ATVBAHA.111.238030. Epub 2011 Nov 23.

PMID:
22116093
36.

Siglec-9 is a novel leukocyte ligand for vascular adhesion protein-1 and can be used in PET imaging of inflammation and cancer.

Aalto K, Autio A, Kiss EA, Elima K, Nymalm Y, Veres TZ, Marttila-Ichihara F, Elovaara H, Saanijoki T, Crocker PR, Maksimow M, Bligt E, Salminen TA, Salmi M, Roivainen A, Jalkanen S.

Blood. 2011 Sep 29;118(13):3725-33. doi: 10.1182/blood-2010-09-311076. Epub 2011 Aug 5.

37.

Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.

Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P.

Ann Rheum Dis. 2011 Sep;70(9):1605-12. doi: 10.1136/ard.2010.143347. Epub 2011 May 28.

PMID:
21623000
38.

Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis.

Nordal E, Zak M, Aalto K, Berntson L, Fasth A, Herlin T, Lahdenne P, Nielsen S, Straume B, Rygg M; Nordic Study Group of Pediatric Rheumatology.

Arthritis Rheum. 2011 Sep;63(9):2809-18. doi: 10.1002/art.30426.

39.

Iron status during anti-TNF therapy in children with juvenile idiopathic arthritis.

Aalto K, Honkanen V, Lahdenne P.

Clin Rheumatol. 2011 Jan;30(1):115-9. doi: 10.1007/s10067-010-1571-7. Epub 2010 Sep 30.

PMID:
20882311
40.

Prevention of acute adverse events related to infliximab infusions in pediatric patients.

Lahdenne P, Wikström AM, Aalto K, Kolho KL.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):785-90. doi: 10.1002/acr.20246.

41.

Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate.

Kivi E, Elima K, Aalto K, Nymalm Y, Auvinen K, Koivunen E, Otto DM, Crocker PR, Salminen TA, Salmi M, Jalkanen S.

Blood. 2009 Dec 17;114(26):5385-92. doi: 10.1182/blood-2009-04-219253. Epub 2009 Oct 27.

42.

The mechanism of primary patellar dislocation: trauma history of 126 patients.

Nikku R, Nietosvaara Y, Aalto K, Kallio PE.

Acta Orthop. 2009 Aug;80(4):432-4. doi: 10.3109/17453670903110634.

43.

Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.

Tynjälä P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, Lahdenne P.

Rheumatology (Oxford). 2008 Mar;47(3):339-44. doi: 10.1093/rheumatology/kem356. Epub 2008 Jan 31.

PMID:
18238789
44.

Assessment of disease activity in juvenile idiopathic arthritis. The number and the size of joints matter.

Berntson L, Wernroth L, Fasth A, Aalto K, Herlin T, Nielsen S, Nordal E, Rygg M, Zak M.

J Rheumatol. 2007 Oct;34(10):2106-11. Epub 2007 Sep 15.

PMID:
17896798
45.

Bone health and growth in glucocorticoid-treated patients with juvenile idiopathic arthritis.

Valta H, Lahdenne P, Jalanko H, Aalto K, Mäkitie O.

J Rheumatol. 2007 Apr;34(4):831-6. Epub 2007 Feb 15.

PMID:
17309121
46.
48.

Nerve growth factor in serum of children with systemic lupus erythematosus is correlated with disease activity.

Aalto K, Korhonen L, Lahdenne P, Pelkonen P, Lindholm D.

Cytokine. 2002 Nov 7;20(3):136-9.

PMID:
12453472
50.

[Abdominal pain in a young woman].

Aalto K, Hulmi T.

Duodecim. 1999;115(18):2023,2027. Finnish. No abstract available.

PMID:
11963924

Supplemental Content

Support Center